MM-111
- Generic Name
- MM-111
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1361108-53-3
- Unique Ingredient Identifier
- 6IJ4CQY76O
- Background
MM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.
- Associated Conditions
- -
- Associated Therapies
- -
Can Merrimack Get A High Five?
Merrimack Pharmaceuticals, a biotech company focused on cancer treatment, has five oncology candidates in clinical development. Its most advanced candidate, MM-398, is in a global phase III study for pancreatic cancer. Merrimack also has candidates like MM-121, developed with Sanofi, in various cancer trials. Despite significant operating losses, the company's IPO raised $100.5 million, funding operations into the second half of 2013.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath